Achieving global mortality reduction targets and universal health coverage: The impact of COVID-19

PLoS Medicine
(Accessed 26 Jun 2021)


Achieving global mortality reduction targets and universal health coverage: The impact of COVID-19
Wenhui Mao, Osondu Ogbuoji, David Watkins, Ipchita Bharali, Eric Boateng, Mohamed Mustafa Diab, Duah Dwomoh, Dean T. Jamison, Preeti Kumar, Kaci Kennedy McDade, Justice Nonvignon, Yewande Ogundeji, Fan-Gang Zeng, Armand Zimmerman, Gavin Yamey
Collection Review | published 24 Jun 2021 PLOS Medicine

COVID-19 and indirect health implications in Africa: Impact, mitigation measures, and lessons learned for improved disease control

PLoS Medicine
(Accessed 26 Jun 2021)


COVID-19 and indirect health implications in Africa: Impact, mitigation measures, and lessons learned for improved disease control
Seth C. Inzaule, Pascale Ondoa, Marguerite Massinga Loembe, Yenew Kebede Tebeje, Ahmed E Ogwell Ouma, John N. Nkengasong
Collection Review | published 23 Jun 2021 PLOS Medicine

The 2021 Ebola virus outbreak in Guinea: Mistrust and the shortcomings of outbreak surveillance

PLoS Neglected Tropical Diseases
(Accessed 26 Jun 2021)


The 2021 Ebola virus outbreak in Guinea: Mistrust and the shortcomings of outbreak surveillance
Manuel Raab, Emmanuelle Roth, Vinh-Kim Nguyen, Guenter Froeschl
| published 24 Jun 2021 PLOS Neglected Tropical Diseases
In February 2021, an outbreak of Ebola virus disease (EVD) was declared in the N’Zérékoré prefecture, located in the southeastern area of Guinea known as “Forest Guinea” [1]. This region is where the 2013 to 2016 West African epidemic—the largest Ebola epidemic to date—started. In the aftermath, Forest Guinea gained the status of a high-risk region for EVD and other viral haemorrhagic fevers [2]. Consequently, outbreak surveillance and preparedness planning have focused on preparing for a recurrence, such as the 2021 resurgence of Ebola.
Surveillance efforts aim for rapid containment through early detection, specific treatments, and an efficient vaccine. In fact, efforts deployed in the region appear to have detected the current resurgence within a time frame of somewhat less than 1 month. Local communities view the current response through the lens of the earlier outbreak and the preparedness efforts that followed. The response to the 2013 to 2016 epidemic in Forest Guinea was characterised by deep mistrust and violence. In its aftermath, preparedness efforts have been met with scepticism in the population, including healthcare workers, with regard to the ability of the public health system being able to manage future outbreaks effectively…

Knowledge, attitude/perception, and practice related to seasonal influenza vaccination among caregivers of young Thai children: A cross-sectional study

PLoS One
[Accessed 26 Jun 2021]


Knowledge, attitude/perception, and practice related to seasonal influenza vaccination among caregivers of young Thai children: A cross-sectional study
Chareeya Thanee, Wanitchaya Kittikraisak, Chalinthorn Sinthuwattanawibool, Koonkoaw Roekworachai, Arunee Klinklom, Katesiree Kornsitthikul, Suwadee Jirasakpisarn, Ussanee Srirompotong, Malinee Chittaganpitch, Fatimah S. Dawood, Piyarat Suntarattiwong, Joshua A. Mott, Tawee Chotpitayasunondh
Research Article | published 25 Jun 2021 PLOS ONE

Perceived enablers and barriers of community engagement for vaccination in India: Using socioecological analysis

PLoS One
[Accessed 26 Jun 2021]


Perceived enablers and barriers of community engagement for vaccination in India: Using socioecological analysis
Tapati Dutta, Jon Agley, Beth E. Meyerson, Priscilla A. Barnes, Catherine Sherwood-Laughlin, Jill Nicholson-Crotty
Research Article | published 25 Jun 2021 PLOS ONE

Success of community approach to HPV vaccination in school-based and non-school-based settings in Haiti

PLoS One
[Accessed 26 Jun 2021]


Success of community approach to HPV vaccination in school-based and non-school-based settings in Haiti
Cynthia Riviere, Tatiana Bell, Yonie Cadot, Christian Perodin, Benedict Charles, Claudin Bertil, Jazreel Cheung, Shalmali Bane, Hoi Ching Cheung, Jean William Pape, Marie Marcelle Deschamps
Research Article | published 24 Jun 2021 PLOS ONE

The Willingness to Receive COVID-19 Vaccine and Its Associated Factors: “Vaccination Refusal Could Prolong the War of This Pandemic” – A Systematic Review

Risk Management and Healthcare Policy
[Accessed 26 Jun 2021]


The Willingness to Receive COVID-19 Vaccine and Its Associated Factors: “Vaccination Refusal Could Prolong the War of This Pandemic” – A Systematic Review
Wake AD
Risk Management and Healthcare Policy 2021, 14:2609-2623
Published Date: 21 June 2021

Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose

25 June 2021 Vol 372, Issue 6549


Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose
By Catherine J. Reynolds, Corinna Pade, Joseph M. Gibbons, David K. Butler, Ashley D. Otter, Katia Menacho, Marianna Fontana, Angelique Smit, Jane E. Sackville-West, Teresa Cutino-Moguel, Mala K. Maini, Benjamin Chain, Mahdad Noursadeghi, UK COVIDsortium Immune Correlates Network, Tim Brooks, Amanda Semper, Charlotte Manisty, Thomas A. Treibel, James C. Moon, UK COVIDsortium Investigators, Ana M. Valdes, Áine McKnight, Daniel M. Altmann, Rosemary Boyton


Science25 Jun 2021 : 1418-1423 Open Access
Previous infection results in enhanced variant cross-protective T and B cell responses to a single BNT162b2 vaccine dose.

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

25 June 2021 Vol 372, Issue 6549


mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
By Leonidas Stamatatos, Julie Czartoski, Yu-Hsin Wan, Leah J. Homad, Vanessa Rubin, Hayley Glantz, Moni Neradilek, Emilie Seydoux, Madeleine F. Jennewein, Anna J. MacCamy, Junli Feng, Gregory Mize, Stephen C. De Rosa, Andrés Finzi, Maria P. Lemos, Kristen W. Cohen, Zoe Moodie, M. Juliana McElrath, Andrew T. McGuire
Science25 Jun 2021 : 1413-1418 Open Access
Previous infection results in enhanced vaccine-induced immune protection against variant B.1.351 and other variants.

For WHO leader, a ‘feeling that we’re failing’

25 June 2021 Vol 372, Issue 6549


In Depth
For WHO leader, a ‘feeling that we’re failing’
By Jon Cohen
Science25 Jun 2021 : 1376-1377 Full Access
Tedros Adhanom Ghebreyesus had expected more social responsibility in the face of a global crisis.
Few have spoken out as forcefully against the global disparity in COVID-19 vaccine distribution as Tedros Adhanom Ghebreyesus, director-general of the World Health Organization (WHO). Tedros, as he prefers to be called, has labeled the inequity “vaccine apartheid” and a “catastrophic moral failure” that has led to a “two-track pandemic.” A global procurement scheme by WHO and other parties to supply vaccines to poorer countries, the COVID-19 Vaccines Global Access (COVAX) Facility, has not had much impact so far.

Immunogenicity and safety of a tetravalent dengue vaccine and a bivalent HPV vaccine given concomitantly or sequentially in girls aged 9 to 14 years in Mexico

Volume 39, Issue 25 Pages 3311-3454 (8 June 2021)


Research article Open access
Immunogenicity and safety of a tetravalent dengue vaccine and a bivalent HPV vaccine given concomitantly or sequentially in girls aged 9 to 14 years in Mexico
Jose Luis Arredondo, Sandra Maria Villagomez Martinez, Maria Concepcion Morales, Stephanie Meyer, … Cesar Mascareñas
Pages 3388-3396

Missed childhood immunizations during the COVID-19 pandemic in Brazil: Analyses of routine statistics and of a national household survey

Volume 39, Issue 25 Pages 3311-3454 (8 June 2021)


Research article Full text access
Missed childhood immunizations during the COVID-19 pandemic in Brazil: Analyses of routine statistics and of a national household survey
Mariangela F. Silveira, Cristian T. Tonial, Ana Goretti K. Maranhão, Antonia M.S. Teixeira, … Cesar G. Victora
Pages 3404-3409

Tracking government spending on immunization: The joint reporting forms, national health accounts, comprehensive multi-year plans and co-financing data

Volume 39, Issue 25 Pages 3311-3454 (8 June 2021)


Research article Open access
Tracking government spending on immunization: The joint reporting forms, national health accounts, comprehensive multi-year plans and co-financing data
Gloria Ikilezi, Steven D Bachmeier, Ian E Cogswell, Emilie R Maddison, … Angela E Micah
Pages 3410-3418

Barriers and activities to implementing or expanding influenza vaccination programs in low- and middle-income countries: A global survey

Volume 39, Issue 25 Pages 3311-3454 (8 June 2021)


Research article Open access
Barriers and activities to implementing or expanding influenza vaccination programs in low- and middle-income countries: A global survey
Alison M. Kraigsley, Kristine A. Moore, Amanda Bolster, Maya Peters, … Joseph S. Bresee
Pages 3419-3427

Psychological Determinants of COVID-19 Vaccine Acceptance among Healthcare Workers in Kuwait: A Cross-Sectional Study Using the 5C and Vaccine Conspiracy Beliefs Scales

Vaccines — Open Access Journal


(Accessed 26 Jun 2021)
Open Access Article
Psychological Determinants of COVID-19 Vaccine Acceptance among Healthcare Workers in Kuwait: A Cross-Sectional Study Using the 5C and Vaccine Conspiracy Beliefs Scales
by Mariam Al-Sanafi and Malik Sallam
Vaccines 2021, 9(7), 701; – 25 Jun 2021
Acceptance of coronavirus disease 2019 (COVID-19) vaccination appears as a decisive factor necessary to control the ongoing pandemic. Healthcare workers (HCWs) are among the highest risk groups for infection. The current study aimed to evaluate COVID-19 vaccine acceptance among HCWs in Kuwait, with […]

Modeling the Impact of COVID-19 Vaccination in Lebanon: A Call to Speed-Up Vaccine Roll Out

Vaccines — Open Access Journal


Open Access Article
Modeling the Impact of COVID-19 Vaccination in Lebanon: A Call to Speed-Up Vaccine Roll Out
by Ghina R. Mumtaz, Fadi El-Jardali, Mathilda Jabbour, a Harb, aith J. Abu-Raddad and Monia Makhoul
Vaccines 2021, 9(7), 697; – 25 Jun 2021
Four months into the SARS-CoV-2 vaccination campaign, only 10.7% of the Lebanese population have received at least one dose, raising serious concerns over the speed of vaccine roll-out and its impact in the event of a future surge. Using mathematical modeling, we assessed […

Predictors of Intention to Vaccinate against COVID-19 in the General Public in Hong Kong: Findings from a Population-Based, Cross-Sectional Survey

Vaccines — Open Access Journal


Open Access Article
Predictors of Intention to Vaccinate against COVID-19 in the General Public in Hong Kong: Findings from a Population-Based, Cross-Sectional Survey
by Elsie Yan, aniel W. L. Lai and Vincent W. P. Lee
Vaccines 2021, 9(7), 696; – 25 Jun 2021
Vaccination is one of the most effective ways to stop the spread of COVID-19. Understanding factors associated with intention to receive COVID-19 vaccines is the key to a successful vaccination programme. This cross-sectional study explored the rate of vaccination intention and identified its […]

Characteristics of Healthcare Workers Vaccinated against Influenza in the Era of COVID-19

Vaccines — Open Access Journal


Open Access Article
Characteristics of Healthcare Workers Vaccinated against Influenza in the Era of COVID-19
by Giorgia Della Polla, rancesca Licata, Silvia Angelillo, Concetta Paola Pelullo, Aida Bianco and
Italo Francesco Angelillo
Vaccines 2021, 9(7), 695; – 24 Jun 2021
Understanding the potential impact of COVID-19 on receiving influenza vaccination among healthcare workers (HCWs) is of utmost importance. The purposes of the present cross-sectional study were to describe the characteristics and to explore the predictors of receiving influenza vaccination among a large cohort […]

Media/Policy Watch

Media/Policy Watch
This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.
We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.
The sheer volume of vaccine and pandemic-related coverage is extraordinary. We will strive to present the most substantive analysis and commentary we encounter.


The Atlantic
Accessed 26 Jun 2021
[No new, unique, relevant content]


Accessed 26 Jun 2021
[No new, unique, relevant content]


The Economist
Accessed 26 Jun 2021
[No new, unique, relevant content]


Financial Times
News in-depth
Indian economy
India’s stricken countryside threatens to undermine recovery
June 27, 2021

Coronavirus latest: Brazil’s Covid inquiry hears testimony over controversial vaccine deal
Brazil’s Covid inquiry hears testimony over controversial vaccine deal
June 25, 2021

Coronavirus latest: Almost half of employed adults in Britain commuting, ONS finds
Israel to reimpose mask requirement despite vaccine success
June 25, 2021


Accessed 26 Jun 2021
8 hours ago
CDC: 4,115 Fully Vaccinated Have Been Hospitalized Or Died With Breakthrough Covid-19 Infections
Although the Covid-19 vaccines offer very good protection, they are not perfect. Covid-19 infections, hospitalizations, and deaths can still occur.
By Bruce Y. Lee Senior Contributor

Breaking  |  
Jun 25, 2021
WHO Urges Fully Vaccinated People To Continue Wearing Masks As Delta Variant Spreads—But No Word From CDC
“People cannot feel safe just because they had the two doses” in areas where community transmission is high, one official said.
By Alison Durkee Forbes Staff


Foreign Affairs
Accessed 26 Jun 2021
[No new, unique, relevant content]


Foreign Policy
Accessed 26 Jun 2021
The First Draft Account of the U.K.’s COVID-19 Catastrophe Is Damning
A new book gives the backstory of a dysfunctional early response.
By Jamie Maxwell, a political journalist in Glasgow, Scotland.

Demands for a Lab Leak Investigation Are a Dangerous Distraction
U.S.-China cooperation is vital for global health efforts.
By Deborah Seligsohn, an assistant professor of political science at Villanova University.
June 18, 2021


New Yorker
Accessed 26 Jun 2021
Medical Dispatch
The Delta Variant Is a Grave Danger to the Unvaccinated
One half of America is protected. The other is approaching a perilous moment in the pandemic.
By Dhruv Khullar
June 23, 2021


New York Times
Accessed 26 Jun 2021
As Parents Forbid Covid Shots, Defiant Teenagers Seek Ways to Get Them
Most medical consent laws require parental permission for minors to get a vaccine. Now some places are easing restrictions for Covid shots while others are proposing new ones.
By Jan Hoffman
PRINT EDITION Teens’ New Way To Defy Parents: Getting Vaccine| June 27, 2021, Page A1

Asia Pacific
In India, concern mounts over a variant called Delta Plus.
The version of the virus has been found in several other countries, too. Officials say that they are gathering data about its strength and emphasize that vaccines are likely to still offer protection.
By Sameer Yasir June 25

Asia Pacific
Indonesia’s Doctors Got Vaccinated With Sinovac, and Got Sick
Facing increased cases and a deadly variant, the Indonesian health system is under strain, as doctors become patients.
By Hannah Beech and Muktita Suhartono June 25

Brazil Passes 500,000 Covid Deaths, a Tragedy With No Sign of Letup
With 2.7 percent of the world’s population, Brazil has suffered 13 percent of the Covid-19 fatalities, and the pandemic there is not abating.
PRINT EDITION June 25, 2021


Washington Post
Accessed 26 Jun 2021
China says no strings attached to vaccine shipments overseas
BEIJING — China said Saturday that it provides vaccines to other countries with no political conditions attached, responding to a story by The Associated Press saying China pressured Ukraine into withdrawing from a multi-country statement on human rights in China’s Xinjiang region by threatening to withhold a COVID-19 vaccine shipment.
A statement from the Chinese Foreign Ministry said it welcomed Ukraine’s decision to take its name off the statement at a meeting of the U.N. Human Rights Council in Geneva, adding “we haven’t heard that Ukraine has encountered any difficulty in importing vaccines from China.”
The Associated Press, citing diplomats from two Western countries, reported that Ukraine had pulled its name from the statement Thursday after China warned it would block a planned shipment of at least 500,000 doses of COVID-19 vaccines unless it did so. The diplomats spoke on condition of anonymity because they were not authorized to discuss the matter publicly…
Associated Press · Jun 26, 2021

Think Tanks et al

Think Tanks et al
Accessed 26 Jun 2021
[No new digest content identified]
Center for Global Development [to 26 Jun 2021]
Who To Prioritise for C19 Vaccines? A Systematic Literature Search and Narrative Review of C19 Models
How best to prioritise COVID-19 vaccination within and between countries has been a public health and an ethical challenge for decision-makers globally, especially given the vaccine supply is limited in the short and medium term. Epidemiological and economic models can support this decision by providing an assessment of the potential health and broader societal impact of competing prioritisation strategies (e.g., age based strategies, strategies based on the occupation or social networks).
Chatham House [to 26 Jun 2021]
Accessed 26 Jun 2021
Members event – Vaccine diplomacy at a time of extreme rivalries
How have vaccine nationalism and vaccine diplomacy become key components of geopolitics?
30 June 2021 — 12:00PM TO 1:00PM

Explainer Video – Vaccine passports: What they are, and are they useful?
Chatham House experts from the Global Health Programme tackle the main questions and issues around the use of vaccine passports.
23 June 2021


Accessed 26 Jun 2021
Podcast Episode
Upcoming Event
Assessing the 2021 G7 Summit: The Sherpa Perspective
June 30, 2021

Upcoming Event
Building Resilience: Implementing Primary Care and Immunization Programs in the Covid-19 Context
June 28, 2021

Global Covid-19 Vaccine Distribution Handbook
June 23, 2021 | By Daniel F. Runde, Conor M. Savoy, Janina Staguhn

Kaiser Family Foundation
[No new digest content identified]

Vaccines and Global Health: The Week in Review :: 20 June 2021

Vaccines and Global Health: The Week in Review is a weekly digest  summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated with the current issue date

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to

– pdf version A pdf of the current issue is available here: 

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy


Milestones :: Perspectives :: Research



UNICEF welcomes G7 leaders’ commitments to donate COVID vaccine doses, calls for accelerated timetable
Statement by UNICEF Executive Director Henrietta Fore
NEW YORK, 13 JUNE 2021 – “We welcome the commitment this week by leaders of G7 nations to accelerate the rollout of safe, effective, accessible and affordable vaccines for the poorest countries, with a goal toward ending the pandemic in 2022. Equitable access to COVID-19 vaccines represents the clearest pathway out of this pandemic for all of us — children included, and commitments announced by G7 members last week are an important step in this direction.

“UNICEF is particularly pleased that some of the dose donations will be made available immediately to supplement ongoing shortfalls. However, time is still of the critical essence.

“UNICEF thanks G7 member states for their pledges and continued support. UNICEF also thanks all our ambassadors and supporters who are sharing their voices in extending a call for immediate and significant dose donations. If we are to make good on the collective pledge of ending the pandemic next year, much work remains.


“Even as many citizens in high-income countries begin to contemplate post-vaccination life, in low-income countries, the future appears quite bleak. More people have died of COVID-19 already this year than in the whole of 2020, led by outbreaks in numerous countries where vaccines remain out of reach. We are particularly worried about the surges in South America, Asia and Africa.

“As the pandemic rages, the virus mutates and produces new variants that could potentially threaten the vaccinated and unvaccinated alike. We are in a fierce race. Donating doses now is smart policy that speaks to our collective best interests.

“Several forecasts suggest that G7 countries will have enough vaccine supplies to donate 1 billion doses by as early as the end of 2021.

“In addition to these generous vaccine pledges, UNICEF and the many organizations and countries involved with distribution and readiness need clear timelines regarding when the vaccines will be available. This is a particularly important element for successfully delivering the vaccines in countries with poor health infrastructure.

“The COVID-19 pandemic has upended the lives of children, affecting every aspect of their lives: their health, education, protection and future prosperity. Now, more than ever, what we do today will have significant and lasting impact on our collective tomorrows. There is no time to waste.”



Outgoing U.N. aid chief slams G7 for failing on vaccine plan
Michelle Nichols
Reuters, 14 June 2021
UNITED NATIONS, June 14 (Reuters) – Outgoing U.N. aid chief Mark Lowcock slammed the Group of Seven wealthy nations on Monday for failing to come up with a plan to vaccinate the world against COVID-19, describing the G7 pledge to provide 1 billion doses over the next year as a “small step.”


“These sporadic, small-scale, charitable handouts from rich countries to poor countries is not a serious plan and it will not bring the pandemic to an end,” Lowcock, who steps down on Friday, told Reuters. “The G7, essentially, completely failed to show the necessary urgency.”

The leaders of the United States, Japan, Germany, Britain, France, Italy and Canada met in Cornwall, England over the weekend and also agreed to work with the private sector, the Group of 20 industrialized nations and other countries to increase the vaccine contribution over months to come.
“They took a small step – at that very, very nice resort in Cornwall – but they shouldn’t kid themselves it’s more than a small step and they have still have a lot to do,” Lowcock said.


“What the world needed from the G7 was a plan to vaccinate the world. And what we got was a plan to vaccinate about 10% of the population of low and middle income countries, maybe by a year from now or the second half of next year,” he said.

In May, the International Monetary Fund unveiled a $50 billion proposal to end the COVID-19 pandemic by vaccinating at least 40% of the population in all countries by the end of 2021 and at least 60% by the first half of 2022.

“That is the deal of the century,” said Lowcock, adding that the G7 could also have done a lot more to provide vital supplies – such as oxygen ventilators, testing kits and protective equipment – to countries who are going to have to wait longer for vaccines.

[In May 2017, Mr. Mark Lowcock of the United Kingdom was appointed as the UN Under-Secretary-General for Humanitarian Affairs and Emergency Relief Coordinator, and head of the UN Office for the Coordination of Humanitarian Affairs (OCHA)]



G7 Summit was a missed opportunity for action and funding needed to end COVID-19 pandemic
June 16, 2021 by PATH
Last week, leaders from the Group of Seven (G7)—Canada, France, Germany, Italy, Japan, the United Kingdom, and the United States—came together to discuss, among other things, an ambitious goal to build stronger health systems to protect the world from future pandemics.

While we were pleased to see a bold commitment from the US government to donate 500 million doses of the Pfizer-BioNTech COVID-19 vaccine to the world’s lowest income nations, the G7 failed to provide an overall blueprint for investment or action that the world desperately needs to end this pandemic and prepare for the next.

Leaders acknowledged the need to vaccinate a majority of the global population to end the pandemic by 2022 but failed to agree on a global roadmap to bolster political will and spur action to achieve herd immunity. The G7 communique rightly prioritizes increased coordination around global vaccine manufacturing capacity, but again lacked any strategy for how do so. And we were pleased to see ongoing support from G7 nations for the extension of the ACT-Accelerator and increased transparency around vaccine procurement and delivery to both donor and recipient countries, but with the current US$18.1 billion funding gap, meaningful support requires greater funding commitments.

World leaders from the wealthiest countries have a responsibility to act—and fund—an inclusive COVID-19 response that will put an end to the acute phase of the pandemic and save lives. We will continue to demand that G7 leaders back their statements with the funding and outline of tangible action needed to bring the world past the current crisis and prepare for the next.

Countries must share COVID-19 vaccine doses; the sooner the better

Milestones :: Perspectives :: Research


Editor’s Note:
We include this opinion piece from Seth Berkley, CEO of Gavi, dated 11 June 2021. We did not identify it as available in time for our last edition.

Countries must share COVID-19 vaccine doses; the sooner the better
OPINION – by Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance
11 June 2021  [Editor’s text bolding]
With nearly half a million new infections globally each day and billions of people still awaiting their first COVID-19 jab it is crucial that, not only must no dose go to waste, but every single dose must be deployed as effectively as possible if we are to bring this pandemic under control. Some of the world’s wealthiest countries nations have already committed to share doses with lower-income countries through COVAX: as G7 leaders meet this week, other governments must follow suit and share their doses now, because we only have a limited window when we can use them.

During a pandemic, timing really is everything, especially when you are in the midst of the largest and most complex vaccine deployment in history. COVAX, which is co-led by my organisation, Gavi, expects to deliver more than 1.8 billion doses to people in 92 lower-income countries by early next year. This is enough to protect around 30% of the population in 91 of these countries, plus a sizable chunk of India’s. Given the rapid rate at which the virus continues to mutate, it’s critical that we vaccinate as many people in these countries, starting with those most at risk, such as the health workers and vulnerable people, as quickly as possible.

COVAX hasn’t been immune to the global supply shortage and disruptions; ours have been magnified by the devastating second wave in India, meaning doses have been reallocated for domestic use. By the end of June, we will be facing a shortfall of 190 million doses. The only way to plug this gap in the short term is for those countries that have doses to share them: not later in the year, when our own supplies pick up again, but now.

A year ago, when scientists and manufacturers were racing to develop COVID-19 vaccines and we were racing to design and build COVAX, well-resourced governments were quick to put in their orders, often on several candidates, not knowing which would succeed. Because of this the vast majority of doses have ended up going to the wealthiest nations, which is why more than a third of people in high-income economies are now vaccinated compared to less than 1% of people in low-income economies who have had their first jab.

COVAX was created to ensure ability to pay did not become a barrier to protection during this pandemic, by making COVID-19 vaccines available to people in least-resourced countries, ones that would otherwise have little or no access to them. It has already delivered nearly 82 million doses to 129 economies and invested hundreds of millions of dollars in strengthening health systems in preparation for mass roll out of vaccines. When our supply channels ramp up again, we anticipate that these health systems will be operating at close to maximum capacity as they race to get these vaccines out and into the arms of people.

From the supply chains and cold storage facilities to data systems and health care workers and data systems, these health systems are standing ready to distribute COVID-19 vaccines, despite their limited resources and having been hit hard by the pandemic. But when the doses start to flow again, they will be absolutely stretched.


That is why we need countries that can spare them to share their doses now, and ideally without being earmarked for specific countries or regions, because if COVAX is to make them equitably available then it needs to be free to distribute them to countries based on need.

This is not just about doing what’s right, but it’s also absolutely to critical stop transmission. Because unless people all around the world are protected, particularly high-risk individuals, then the virus will continue to circulate, and new variants will emerge. So, while some governments may prefer to specify which countries or regions they wish to share their doses with through COVAX, the more doses are earmarked like this, the more difficult it will be for COVAX to achieve truly equitable access.

The vaccine race has now turned into a race against time. COVAX needs doses now, while its supplies are low and when countries have the ability to deliver them. G7 governments need to lead the way and encourage other governments to share doses immediately. Because it would be a tragedy to get them too late, when there are millions of people elsewhere in such desperate need of them. Every dose that is not put to immediate use not only puts a life at risk, but it potentially delays an end to this crisis.

A beautiful idea: how COVAX has fallen short

Featured Journal Content


Editor’s Note:
We anticipate that Gavi/COVAX will respond to elements of this report and we will present any response on our next edition.


The Lancet
Volume 397, ISSUE 10292,
P2322-2325, June 19, 2021
World Report
A beautiful idea: how COVAX has fallen short
Ann Danaiya Usher
Published:June 19, 2021 DOI:
COVAX was meant to supply COVID-19 vaccines for all based on solidarity and equity. Instead, it relies on rich countries’ willingness to share their doses. Ann Danaiya Usher reports.

Launched 1 year ago, the COVAX facility was conceived as an “unparalleled and ambitious” attempt to create a global procurement mechanism to supply COVID-19 vaccines to all countries in the world. It was hailed as a “global, heroic effort” that would “transcend the limits of human ingenuity” to ensure that vaccine development progressed as fast as possible, at “a speed, scale, and access never before seen in human history”. Underlying everything, according to early descriptions by Gavi, the Vaccine Alliance, it was “single minded in its goal to ensure equitable access to COVID-19 vaccines”.

This vision has not come to pass. At the pledging summit for COVAX on June 2, 2021, hosted by Japan, Gavi finally reached its US$8·3 billion ask for the procurement and delivery of vaccines for the 92 eligible low-income and middle-income countries (LMICs) this year. However, even with full financing, the COVAX roll-out has moved much more slowly than that in high-income countries (HICs). Speaker after speaker at the summit lamented the gross inequity in access to vaccines. “Today, ten countries have administered 75% of all COVID-19 vaccines, but, in poor countries, health workers and people with underlying conditions cannot access them. This is not only manifestly unjust, it is also self-defeating”, UN secretary general António Guterres told the gathering. “COVAX has delivered over 72 million doses to 125 countries. But that is far less than 172 million it should have delivered by now.” Of the 2·1 billion COVID-19 vaccine doses administered worldwide so far, COVAX has been responsible for less than 4%.


”Born out of solidarity”
Gavin Yamey at Duke University (Durham, NC, USA) was part of a working group, convened by Gavi in early 2020, to discuss the design of COVAX. “It was a beautiful idea, born out of solidarity”, he said. “Unfortunately, it didn’t happen…Rich countries behaved worse than anyone’s worst nightmares.”

COVAX, managed by Gavi, along with the Coalition for Epidemic Preparedness Innovations and WHO, was designed to stand on two legs: one for HICs, which would pay for their own vaccines, and the other for 92 lower-income countries, whose doses would be financed by donor aid.

In the so-called self-financing leg of COVAX, HICs were asked to pay upfront by mid-September, 2020, for the option to buy vaccines for their own populations. The UK, for example, paid £71 million for 27 million doses from COVAX, and Canada paid CA$220 million for 15 million doses. Australia, New Zealand, Norway, and South Korea also bought vaccine options from COVAX as self-financing countries.

In the other leg of COVAX, vaccines for lower-income countries would be financed with donor grants through an Advance Market Commitment (AMC). The poorest of the 92 countries would receive them at no cost. Team Europe (led by Germany) and the USA have together provided US$5 billion to the COVAX AMC, Japan has given US$1 billion, and the UK, US$735 million. Most of these funds have been pledged only in the past few months.

The grand idea of COVAX was that the combination of these two funding streams—the self-financed part and the aid-financed AMC—would give the facility the means to invest in research and development of several promising vaccine candidates. Additionally, as a pooled procurement mechanism, COVAX would have the financial muscle as a buyer to drive down prices for all participants. Once any of the COVAX portfolio vaccines had successfully undergone clinical trials and proved themselves to be both safe and effective, both self-financing and AMC countries would be allocated vaccines at the same rate, proportional to their total population size.

COVAX would be “quite literally a lifeline” for self-financing countries that had not made any bilateral deals with vaccine manufacturers, Gavi’s chief executive officer Seth Berkley explained last autumn. However, by August, 2020, the USA had already entered into seven bilateral deals with six companies for more than 800 million doses, enough to vaccinate 140% of its population, according to the Duke University Launch and Scale Speedometer. The EU was close behind with access to half a billion doses secured through two deals. The UK had bought into five bilateral deals giving it access to 270 million doses, equivalent to 225% of its population. These early investments by rich countries in multiple vaccines secured them a place at the front of the queue. Because COVAX did not have the means to compete, it was pushed to the back.

Writing in a blog post earlier this year, Andrea Taylor, who manages the Launch and Scale Speedometer vaccine tracker, has said that “COVAX was premised on an all-for-one-and-one-for-all approach to defeating the pandemic”, adding that “this would have led to the best outcomes for everyone and was our best hope for ending the pandemic quickly. But we also know from experience that the world doesn’t really work this way.”

Everyone knew that rich countries would enter into bilateral vaccine deals, Yamey said. But it was hoped that they would also buy into COVAX as insurance in case some vaccine candidates did not prove successful. Most of them did not. In the end, “three dozen countries bypassed COVAX and made huge deals directly with manufacturers. They were very lucky that the vaccines worked out. And since they cleared the shelves, there were not enough doses left for COVAX”, he said.


As rich countries busily signed bilateral agreements with individual vaccine manufacturers and the interest in engaging with COVAX faded, Gavi gave up on the original idealistic approach and made two key concessions that would sweeten the deal for self-financing participants.

Initially, all countries were to receive equal treatment by COVAX. They would have access to vaccines at the same time and participants would be allowed to purchase enough doses to cover 20% of their populations. Moreover, participants were to be “product agnostic”, in the sense that COVAX would decide on the products and allocation of volume of doses.

Breaking with the principle of equal treatment, Gavi created a second category of purchase options for self-financing countries, called the Optional Purchase Arrangement, which gave buyers the possibility to opt in or out of certain products; basically, giving them more choice about which vaccines they would receive. That is, if a country was offered vaccine A but did not want it, it would not be obliged to take it, and could instead save its options for purchase of another product. “The trade-off for these participants, who will have greater choice, is that they will be required to pay a higher proportion of the total cost per dose upfront”, states a Gavi explainer. This, Kate Elder at Médecins Sans Frontières said, was done in response to pressure from the UK. “Gavi bent over backwards and let the UK basically dictate another option for joining COVAX”, she said.

A second concession made by Gavi to potential self-financing countries—but not open to lower-income countries—was an increase in the volume of vaccine they were permitted to purchase. While countries eligible for the AMC window were intended to receive vaccines to cover up to 20% of their populations, the ceiling for self-financing countries was raised to 50%.

Elder points to the blatant inequity built into this arrangement. She said Gavi lost valuable time last year coaxing rich countries to join COVAX. “The theory that you would get every country to buy into this global procurement mechanism seemed very naive”, she said. “COVAX sacrificed speed to convince governments to join the initiative, when clearly [those governments] were going to take other steps to secure vaccines. I think acquiescing to the ‘suggestions’ of a small group of HICs led to the overall weakening of COVAX, because it introduced a lot of uncertainty in the mechanism itself…The delayed timeline also led to a delay in the fundraising.”

The report of the Independent Panel for Pandemic Preparedness and Response also pointed to the harm caused by the slow mobilisation of resources for COVAX: “Had COVAX had sufficient and readily available early funding it would have been better able to secure enough immediate supply to meet its aims”, it states.

“If we had secured financing earlier, then we could have locked in doses earlier, as opposed to the second half of this year when COVAX’s volume will start ramping up”, Gavi’s spokesperson told The Lancet.

Yamey said the concessions that were offered to wealthier nations “speak to the effort to incentivise rich countries to join COVAX. For future pandemics, we have to figure out how to overcome this problem. I think that we need a compulsory mechanism where every nation participates now. Otherwise, you need to find stronger incentives… This is a difficult nut to crack.”

Gavi’s spokesperson said that “COVAX was set up as a multilateral mechanism, and active engagement and collaboration has been its driving force since June, 2020, when it was launched. COVAX’s governance structure is designed so that lower-income economies and self-financing countries all have a say in the strategic direction of the Facility.”


Gavi’s predicament
The failure to entice wealthy countries to join COVAX in large numbers has left the managers of the facility in an awkward situation. On one hand, not enough self-financing participants joined COVAX to give it the massive buying power that was hoped. On the other, even though COVAX is desperately short of vaccine, the facility is now contractually obliged to reserve one in five doses for a few rich countries. As of late May, COVAX had supplied about 80 million doses to LMICs; 22 million doses had gone to HICs.

While the access inequities have widened, Gavi has had to justify sending vaccines to countries that have already vaccinated a large portion of their populations at the same time as deliveries to the very poorest countries have barely begun. This uncomfortable predicament is palpable in Gavi’s messaging about COVAX, which now rarely, if ever, mentions the self-financing part of the facility.

Although Gavi has produced numerous press releases about deliveries of vaccines to LMICs, starting with the shipment of 600 000 doses of the Oxford University–AstraZeneca vaccine to Ghana on Feb 24, 2021, there was no announcement when Canada was allocated 1·62 million doses of the same vaccine earlier that month, and no fanfare when 500 000 doses of the Pfizer–BioNTech vaccine were assigned by COVAX to the UK in April.

Oxfam criticised Canada for the delivery, accusing the Government of taking doses from the poor when it has signed bilateral deals with manufacturers for enough vaccine to cover four times the country’s population. “Canada should not be taking the COVAX vaccine from poor nations to alleviate political pressures at home”, Diana Sarosi at Oxfam Canada said. However, strictly speaking, Canada was merely following through on the terms of its agreement with COVAX. Public services and procurement minister Anita Anand said as much when she defended the move in a comment to CBC. Canada is “entitled under our agreement with COVAX to draw down on the commitment that we made with them back in the summer”, she said.

Similarly, responding to a question in parliament in March, 2021, the UK under-secretary for health and social care Nadhim Zahawi explained that COVAX had enabled “high- and upper-middle income countries to pool investments in potential vaccine candidates”. Both the Canadian and British governments pointed to their generous donations to the AMC part of COVAX, which is dedicated to supplying vaccine to poor countries.

The self-financing window of COVAX has also disappeared from the budget of the Access to COVID-19 Tools Accelerator (ACT-A), of which the COVAX facility is a part. The first iteration of the budget in September, 2020, had a total financial frame of US$38 billion. By March, 2021, the ask had dropped to US$33 billion. Norway’s Global Health Ambassador John-Arne Røttingen, a Gavi board member, explained why this happened: “The fundraising necessary for the COVAX facility and the fundraising for ACT-A when it comes to vaccines is only relevant for the AMC window and not for the self-financing countries, since that is where we mobilise collective finance. That is why we took that out of the budgeting.”


COVAX needs more doses
COVAX now aims to roll out 2·3 billion doses of COVID-19 vaccines worldwide by early 2022. According to the latest COVAX global supply forecast, dated April 7, 2021, 485 million doses of these are earmarked for self-financing countries, while 1·8 billion doses will go to the 92 lower-income countries, with at least 1·3 billion of those doses available at no cost to their governments.

This volume of doses is not assured: “If the forecast comes to pass—and that is a big if, with uncertainties around capacity, funding, and country readiness—this means that COVAX should be able to reach at least 27 per cent of the population of lower-income countries across the world in 2021, well above the 20 per cent target it set upon its inception”, Gavi states. Many have questioned the original COVAX target of 20%. Even 27% coverage will leave countries that are reliant on COVAX well short of the volume of vaccines they need to achieve herd immunity.

“I have always thought that the 20% target was unfair from the start. No high-income country would tolerate vaccinating only 20% of its population by the end of this year”, said Lawrence Gostin at Georgetown University. Comparing the 20% vaccination target for LMICs with the 50% coverage that was offered to HICs through the self-financing window, he said: “We can’t have double standards.”

WHO estimates that the world needs at least 11 billion doses of vaccine to stamp out the pandemic, and the European Commission has warned that new variants of SARS-CoV-2 that are more transmissible and more deadly could “[push] the demand far beyond the 11 billion doses originally estimated”.

Underlining the scale of the challenge, The People’s Vaccine Alliance—a coalition of organisations including Oxfam and Amnesty International, health experts, and world leaders, that has lobbied for a waiver on COVID-19-related patents—estimates that, at the current rate, low-income countries could take 57 years to fully vaccinate their populations, whereas G7 countries might reach that milestone in the next 6 months.

Against this backdrop, and recognising that wealthy countries have ordered more vaccine doses than they need, dose sharing has emerged as a way to radically increase COVAX’s access to doses. As of late May, 2021, HICs had promised to share 200 million doses with COVAX. Many, including the International Monetary Fund and the Bill & Melinda Gates Foundation, argued that 1 billion doses can and should be shared this year. The Independent Panel recommended that at least 1 billion vaccine doses be shared by no later than Sept 1, 2021, and more than 2 billion doses by mid-2022.

There were therefore huge expectations for last week’s G7 summit, both for dose sharing and for more funding of tools other than vaccines provided through ACT-A, such as protective equipment for health workers, tests, and medical oxygen, the demand for which has increased five times compared with pre-pandemic levels. The group of wealthy countries did not commit new funding for ACT-A, and ended up pledging only 870 million doses over the next year “primarily to COVAX”.

It is uncertain how quickly this will result in vaccines being administered. The Biden administration’s decision to donate 500 million doses of the Pfizer–BioNTech COVID-19 vaccine has caused concern because many countries lack the necessary cold-chain infrastructure. Additionally, while the UK has promised to give away 100 million doses “within the next year”, most of these will not be released until 2022.

The G7 pledge was roundly criticised by Amnesty International, which called it “a drop in the ocean [that] wouldn’t come close to covering the population of India, let alone vaccinating the world’s population” and said that “G7 leaders have opted for more of the same paltry half measures and insufficient gestures”.

Moreover, the G7 communique commits to deliver only half of the 870 million doses by the end of the year—ie, around 450 million doses. Since COVAX is contractually obliged to deliver 485 million of the 2·3 billion doses to self-financing (high-income) countries this year, the G7 dose-sharing pledge does not quite match the volume of vaccines that rich countries are set to take out of COVAX for their own domestic programmes.


The COVAX model
Taylor likens the process of designing COVAX to building a car while you are driving it. In early 2020, the shape and timeline of the pandemic were unknown, the symptoms of the disease were not well understood, and no-one knew how long it would take for one or more vaccines to be developed.

The original notion of a global vaccine hub more or less collapsed, and COVAX ended up using a traditional aid-financed approach, which has left lower-income countries wholly at the mercy of wealthy nations and profit-driven companies.

“It is still this model of seeing how much money you can bring in and then seeing what you can negotiate with industry based on that money”, said Elder. “The promise of COVAX from the beginning that it would be the most attractive buyer for industry because it represented the ‘global need’ obviously did not pan out.” For any future iterations of COVAX, Taylor has argued that since national leaders have a responsibility to protect their own populations, vaccine nationalism is inevitable and this should be integrated into the design from the start.

Several global health experts point to the failure to recognise supply constraints as a major obstacle to global vaccination and emphasise diversifying and scaling up manufacturing from the beginning. This lack of recognition was a serious flaw in the COVAX design, said Gostin. “Supply shortages should have been anticipated and ramping up supplies should have been baked into the design of COVAX from the start.”

The Gavi spokesperson said many lessons have been learned along the way. “We need to start expanding vaccine manufacturing—in particular in the Global South—now, if we want to respond better during the next pandemic. Other innovations COVAX has developed, such as its universal no-fault compensation scheme, have made it easier for manufacturers to provide vaccines to lower-income countries and will help future responses too.”

The UN secretary general has called for a global task force on vaccination that would bring together ACT-A partners with the multilateral system and would be able to “deal with pharmaceutical companies”. Guterres implies an approach that is much tougher on industry than ACT-A and COVAX’s voluntary, partnership-based approach.

“Guterres is right”, said Gostin. “There can be no solution to the global vaccine crisis without governments placing pressure on big pharma, including waiving intellectual property rights and technology transfer. It is literally impossible to ramp up vaccine supplies unless we have more manufacturing hubs, including in lower-income countries.”

Recognising the shortcomings of COVAX is likely to be important far beyond the current pandemic. The COVAX approach is already being touted as a possible model for dealing with future pandemics and other global crises, such as climate change. In a report on development cooperation during 2020, Susanna Moorehead, chair of the OECD Development Assistance Committee, writes: “Lessons from the COVAX facility can inform the design of co-ordinated platforms to promote global public goods, including those to mitigate the impact of climate change.” In a similar vein, the Independent Panel proposes that ACT-A, including COVAX, could serve as a model for a permanent mechanism that would transform HIC-dominated systems to a global, inclusive approach. “ACT-A provides a valuable model. Lessons drawn from both its strengths and weaknesses should guide the establishment of a permanent platform which can stand in readiness for any future pandemic.”

Yamey warns that the success of COVAX and ACT-A is far from assured. He and colleagues have argued that monopolies on knowledge and production that benefit a handful of companies have locked lower-income countries out, while rich countries have used their power to put their populations ahead of the most vulnerable globally. “I have a dog in the race—I would like to see the COVAX thrive [but] unless we address these structural issues, what advantage is there to making ACT-A permanent?”

COVID-19 Data Explorer: Global Humanitarian Operations

Featured Journal Content


COVID Vaccines – OCHA:: HDX

COVID-19 Data Explorer: Global Humanitarian Operations
COVID-19 Vaccine Roll-out
Jun 19, 2021 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | DATA


Global COVID-19 Figures: 171M total confirmed cases; 3.8M total confirmed deaths
Global vaccines administered: 2.54B
Number of Countries: 26 [26]
COVAX First Allocations (Number of Doses): 73M [73M]
COVAX Delivered (Number of Doses): 15M [15M]
Other Delivered (Number of Doses): 34M [33M]
Total Delivered (Number of Doses): 49M [49M]
Total Administered (Number of Doses): 41M [36M]

Coronavirus [COVID-19] – WHO Public Health Emergency of International Concern (PHEIC)

Featured Journal Content


Coronavirus [COVID-19] – WHO
Public Health Emergency of International Concern (PHEIC)


Weekly Epidemiological and Operational updates
Last update: 18 Jun 2021
Confirmed cases :: 177 108 695 [week ago: 174 918 667]
Confirmed deaths :: 3 840 223 [week ago 3 782 490]
Vaccine doses administered: 2 378 482 776 [week ago: 2 156 550 767]



Weekly operational update on COVID-19 – 14 June 2021
In this edition of the COVID-19 Weekly Operational Update, highlights of country-level actions and WHO support to countries include:
:: Support for Bolivia to become part of the regional genomic surveillance network
:: A 69-year-old woman from Ghana shares her COVID-19 vaccination experience
:: Support to the Republic of Moldova to carry out an Emergency Care System Assessment
:: WHO tri-regional policy dialogue on the international mobility of health professionals
:: Global OpenWHO COVID-19 enrolments and survey results showing positive feedback for Partners Platform
:: Progress on a subset of indicators from the SPRP 2021 Monitoring and Evaluation Framework
:: Updates on WHO’s financing to support countries in SPRP 2021 implementation and provision of critical supplies.


Weekly epidemiological update on COVID-19 – 15 June 2021
In the past week, the number of new COVID-19 cases and deaths continued to decrease, with over 2.6 million new cases and 72 000 new deaths reported globally. While the number of cases reported globally now exceeds 175 million, over the past week, the lowest weekly case incidence since February 2021 was reported. Declines in the number of new weekly cases, compared to the previous week, were reported across all Regions except for the African Region. The number of new deaths reported in the past week decreased across all the regions except for the African and South-East Asia Regions.
In this edition, a special focus update on variants is provided, including a newly designated variant of interest (VOI), along with the geographical distribution of variants of concern (VOCs) Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2). This edition also includes an update about strengthening public health intelligence through event-based surveillance, specifically learning from the COVID-19 pandemic.




Draft landscape and tracker of COVID-19 candidate vaccines
18 June 2021
The COVID-19 vaccine tracker and landscape compiles detailed information of each COVID-19 vaccine candidate in development by closely monitoring their progress through the pipeline.


Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 28 May 2021
For 19 vaccine candidates, presents Manufacturer, Name of Vaccine, NRA of Record, Platform, EOI Accepted Status, Pre-submission Meeting Held Status, Dossier Accepted for Review, Status of Assessment; Anticipated/Completed Decision Date
[click on the link above for full scale view]


Updated recommendations for use of Pfizer–BioNTech, Moderna and Janssen vaccines against COVID-19
15 June 2021
The interim recommendations  for use of Pfizer-BioNTech BNT162b2, Moderna mRNA–1273 and Janssen Ad26.COV2.S vaccines have been updated to reflect latest evidence.
Pfizer-BioNTech BNT162b2 vaccine
Moderna mRNA–1273 vaccine
Janssen Ad26.COV2.S vaccine

COVID Vaccine Developer/Manufacturer Announcements [relevant press releases/announcement from organizations from WHO EUL/PQ listing above]

Featured Journal Content


COVID Vaccine Developer/Manufacturer Announcements [relevant press releases/announcement from organizations from WHO EUL/PQ listing above]


Press Releases
AstraZeneca welcomes Court ruling on supply of its COVID-19 vaccine to Europe
18 June 2021
AstraZeneca today welcomed the ruling by the Court of First Instance in Brussels. The European Commission had requested 120 million vaccine doses cumulatively by the end of June 2021, and a total of 300 million doses by the end of September 2021. The judge ordered delivery of 80.2 million doses by 27 September 2021. To date, the Company has supplied more than 70 million doses to the European Union and will substantially exceed 80.2 million doses by the end of June 2021. All other measures sought by the European Commission have been dismissed, and in particular the Court found that the European Commission has no exclusivity or right of priority over all other contracting parties…


COVID-19 Vaccine AstraZeneca effective against Delta (‘Indian’) variant
15 June 2021
New data from Public Health England (PHE) demonstrated COVID-19 Vaccine AstraZeneca offers high levels of protection against the Delta variant (B.1.617.2; formerly the ‘Indian’ variant).
Real world data from PHE, published as a pre-print, demonstrated two doses of COVID-19 Vaccine AstraZeneca are 92% effective against hospitalisation due to the Delta variant and showed no deaths among those vaccinated. The vaccine also showed a high level of effectiveness against the Alpha variant (B.1.1.7; formerly the ‘Kent’ variant) with an 86% reduction of hospitalisations and no deaths reported…


Update on AZD7442 STORM CHASER trial in post-exposure prevention of symptomatic COVID-19
15 June 2021
– Website not responding at inquiry [fourth week]

BioCubaFarma – Cuba
Últimas Noticias
Inicia aplicación de la 1ra dosis en el ensayo con población pediátrica. 

Resumen:  Los primeros voluntarios son 25 adolescentes de 12 a 18 años reciben la primera dosis del candidato vacunal  desarrollado por el Instituto Finlay de Vacunas (IFV).
[Google translate:
Application of the 1st dose begins in the trial with the pediatric population.
Summary: The first volunteers are 25 adolescents from 12 to 18 years of age who receive the first dose of the vaccine candidate developed by the Finlay Vaccine Institute (IFV).]


News – No new digest announcements identified

Clover Biopharmaceuticals – China
News – No new digest announcements identified


Curevac [Bayer Ag – Germany]
CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV
June 16, 2021
:: Pivotal study conducted in 10 countries in fast changing environment of at least 29 COVID-19 variant strains; original strain almost completely absent
:: At second interim analysis, statistical success criteria not met. Favorable safety profile confirmed
:: Initial analyses show trend for age and variant dependent efficacy
:: Results communicated to EMA, study progressing to final analysis within the next few weeks
CureVac N.V. (Nasdaq: CVAC), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced results of the second interim analysis of its international pivotal Phase 2b/3 study in approximatively 40,000 subjects (the HERALD study) of CureVac’s first-generation COVID-19 vaccine candidate, CVnCoV. In the unprecedented context of at least 13 variants circulating within the study population subset assessed at this interim analysis, CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19 disease of any severity and did not meet prespecified statistical success criteria. Initial analyses suggest age and strain dependent efficacy. Available data were communicated with the European Medicines Agency (EMA). The Data Safety Monitoring Board (DSMB) confirmed a favorable safety profile for CVnCoV. The study is continuing to the final analysis and the totality of the data will be assessed for the most appropriate regulatory pathway…


Gamaleya National Center
Latest News and Events – No new digest announcements identified [See Russia/RFID below]

Home – No new digest announcements identified


Press Releases – No new digest announcements identified


Press Releases
June 16, 2021
U.S. Government Purchases Additional 200 Million Doses of Moderna’s COVID-19 Vaccine

June 15, 2021
Moderna and Magenta Partner to Distribute Moderna’s COVID-19 Vaccine and Updated Variant Booster Candidates in United Arab Emirates

June 14, 2021
Dr. Paul Burton to Join Moderna as Chief Medical Officer
June 14, 2021

Moderna Submits Authorization Application for its COVID-19 Vaccine in Adolescents in Switzerland


Press Releases
Novavax to Participate in National Vaccine Advisory Committee Meeting

Novavax Announces Positive Results from First Study of Influenza Vaccine and COVID-19 Vaccine Candidate Administered Simultaneously
– COVID-19 vaccine candidate efficacy in those 18 to <65 years old was preserved in influenza vaccine recipients – Influenza vaccine immunogenicity preserved – Study demonstrated no early safety concerns – Data available ahead of publication via preprint server, medRxiv Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial
:: 93% efficacy against predominantly circulating Variants of Concern and Variants of Interest
:: 91% efficacy in high-risk populations
:: 100% efficacy against variants “not considered Variants of Concern/Interest”
:: All COVID-19 hospitalizations/death occurred in the placebo group
:: Company to host investor conference call today at 8:30 am ET


Recent Press Releases
Data Published in New England Journal of Medicine Shows Pfizer’s Tofacitinib Meets Primary Endpoint in Brazilian Study in Patients Hospitalized with COVID-19 Pneumonia
Wednesday, June 16, 2021


Sanofi Pasteur
Press Releases – No new digest announcements identified


Serum Institute of India
NEWS & ANNOUNCEMENTS – No corporate announcements identified
[Last media release April 21, 2021]


News – Website not responding at inquiry


Press Releases
SINOVAC’s EV71 vaccine Inlive® is approved for children aged from 6 to 71 months [Enterovirus]



Vector State Research Centre of Viralogy and Biotechnology
Home – No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]



Press releases for media – No new digest announcements identified

Duke – Launch and Scale Speedometer

Featured Journal Content


Duke – Launch and Scale Speedometer

[accessed 19 June 2021]


17.9 billion doses reserved
Countries have purchased vaccine doses from a wide pool of candidates to cover their populations. So far, confirmed purchases cover 11.9 billion doses, with another 6 billion doses currently under negotiation or reserved as optional expansions of existing deals…

High-income countries hedged their bets while low-income countries were left out
In 2020, many high-income countries hedged their bets by purchasing enough doses to vaccinate their populations several times over, even before any candidates were approved and have continued to procure more doses of approved vaccines in 2021, in an effort to receive doses as quickly as possible. Because of global manufacturing constraints, the direct deals made by high-income (and some middle-income) countries mean that a smaller piece of the pie is available for low- and middle-income countries and for equity-focused partnerships like COVAX in 2021…

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Featured Journal Content


U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Vaccines and Related Biological Products Advisory Committee
:: No meetings scheduled



White House [U.S.]
Briefing Room – Selected Major COVID Announcements
Remarks by President Biden on the COVID-19 Response and the Vaccination Program
June 18, 2021 • Speeches and Remarks

FACT SHEET: 300 Million Shots in 150 Days: The President’s COVID-19 Strategy is Delivering for Americans
June 18, 2021 • Statements and Releases

Press Briefing by White House COVID-19 Response Team and Public Health Officials
June 17, 2021 • Press Briefings

Remarks by Vice President Harris at a COVID Vaccination Mobilization Event
June 14, 2021 • Speeches and Remarks

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Featured Journal Content


Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment


European Medicines Agency
News & Press Releases
– No new digest announcements identified


European Centre for Disease Prevention and Control
Latest Updates
EASA/ECDC update air travel guidelines to factor in vaccination and latest scientific evidence
Press release – 17 Jun 2021
ECDC and The European Union Aviation Safety Agency (EASA) today issued a new version of the Aviation Health Safety Protocol providing clear operational guidance and risk-based recommendations for health-safe air travel to complement the European Union’s initiatives, such as the EU Digital COVID Certificates.
The new version of the document takes into account new evidence and information such as the circulation of variants of concern (VOCs) and the rollout of the COVID-19 vaccination programmes. The new version  also emphasises  the need to keep non-pharmaceutical measures in place – such as the wearing of medical face masks, hygiene measures and physical distancing. It is intended to provide support to national authorities in the Member States and to aviation stakeholders and is based on the latest scientific evidence, epidemiological situation and policy developments.
“We have reached a significant milestone in the pandemic: a real change in approach that can allow travellers to fly again without worrying excessively that the rules may change at short notice, complicating their journey or making it impossible,” said EASA Executive Director Patrick Ky. “The industry – and passengers – have been waiting for this moment for a long time. Thanks to the expert epidemiological input from ECDC we are confident that this protocol offers practical and pragmatic guidelines for health-safe travel.”…

ECDC supports EU/EEA Member States in rapid detection of SARS-CoV-2 variants
News story – 16 Jun 2021

ECDC begins epidemic monitoring of the EURO 2020/2021 Football Championship
News story – 15 Jun 2021


European Commission
Press release 18 June 2021
Belgian Court orders AstraZeneca to deliver vaccine doses to the EU
Today, the Court of First Instance of Brussels decided to grant interim measures in the case brought against AstraZeneca by the European Commission and the 27 EU Member States.
The court orders AstraZeneca to urgently deliver 50 million doses of vaccine by 27 September 2021 – according to a binding schedule:
:: 15 million doses by 26 July, at 9 a.m.,
:: 20 million doses by 23 August,
:: 15 million doses at 27 September.
In the event of non-compliance with these delivery deadlines AstraZeneca will have to pay a penalty of €10 per dose not delivered.
The judge’s decision on the requested interim measures is based on the fact, that AstraZeneca committed a serious breach (‘faute lourde’) of its contractual obligations with the EU.
The court also holds that AstraZeneca should have deployed all its efforts to deliver the vaccines within the agreed timetable including the British production sites explicitly mentioned in the contract – especially given the big delays in deliveries to the EU.
The President of the European Commission, Ursula von der Leyen, welcomes the decision. “This decision confirms the position of the Commission: AstraZeneca did not live up to the commitments it made in the contract. It is good to see that an independent judge confirms this”, President von der Leyen says. “This shows that our European vaccination campaign not only delivers for our citizens day by day. It also demonstrates, that it was founded on a sound legal basis.”

Questions and answers15 June 2021
Questions & Answers on the latest update regarding the coordination of COVID-related measures restricting free movement in the European Union

Statement 14 June 2021
EU clears way for the EU Digital COVID Certificate
Today, the Presidents of the three EU institutions, the European Parliament, the Council of the EU and the European Commission attended the official signing ceremony for the Regulation on the EU Digital COVID Certificate, marking the end of the legislative process.

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Featured Journal Content


India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment


Ministry of Health and Family Welfare

Guidelines for Management of COVID-19 in Children

Guidelines on Operationalisation of COVID care services for children and adolescents

Government of India – Press Information Bureau
Latest Press Releases
PM launches ‘Customized Crash Course programme for Covid 19 Frontline workers’
Posted on: 18 Jun 2021

Indian Council for Medical Research (ICMR)
No new digest content identified.

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Featured Journal Content


China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

China approves emergency use of domestic vaccines for 3-17 age group
Updated: 2021-06-15 | Xinhua
BEIJING — China has approved the emergency use of its domestic inactivated vaccines against COVID-19 on people aged from 3 to 17, according to a press conference held on June 11.

Currently, China’s mass-vaccination campaign mainly targets adults aged over 18, with over 800 million vaccine doses administered across the country so far, said Chinese Center for Disease Control and Prevention expert Shao Yiming, at the press conference.

China’s mass-vaccination campaign so far has proved that its domestically-made vaccines are safe and effective, Shao said.

Following their authorized use for adults, the Sinopharm and Sinovac vaccines, both developed by China’s pharmaceutical institutions, have been proven safe for the 3-17 age group after clinical trials and expert reviews, and are now authorized for emergency use by the age group by related authorities, said Shao.

Based on the specific pandemic situation, disease-control requirements and the targeted age group’s characteristics, China will organize medical experts to formulate detailed policies on newly-granted vaccinations for people aged 3 to 17, and see that the effort is carried out in a safe and effective manner by the relevant authorities, said Cui Gang, an official with the disease control department of China’s National Health Commission (NHC)…

[See also China CDC section below]

POLIO Public Health Emergency of International Concern (PHEIC)


Public Health Emergency of International Concern (PHEIC)

Polio this week as of 15 June 2021
:: The GPEI is deeply saddened by the reports of attacks on health workers in Afghanistan.  We wish to extend our deepest condolences to the families, relatives and colleagues of the victims. These incidents are a somber reminder of the difficult and often dangerous environments health workers operate in. Health workers must never be a target and any attack on health care providers remains completely unacceptable. All parties must respect and uphold the neutrality of health interventions and ensure the safety of all health workers, who are working across the country to prevent disease and improve the health of communities.

:: Delivering on the Promise of a Polio-free World:  the new Polio Eradication Strategic Plan 2022-2026, was launched at a virtual event on 10 June 2021. The Strategic Plan has been developed in close consultation across the Global Polio Eradication Initiative (GPEI) stakeholdership and lays out the roadmap to securing a lasting polio-free world. Key to success will be the ongoing commitment of all partners around the world, to ensure the Plan can be fully implemented.  The launch event brought together senior leadership of the Governments of Pakistan, Afghanistan, the Democratic Republic of Congo as well as the core partners of the GPEI.

:: The Heads of State of the G7 countries, at the annual meeting held in the UK on 11-13 June 2021, in their official communiqué, highlighted the need for increased global efforts to detect global public health threats, by building international surveillance on existing networks such as polio surveillance.

:: Philippines outbreak officially closed: with no new virus detected in the Philippines in more than 16 months as a result of comprehensive outbreak response, the outbreak has officially been closed.  The Global Polio Eradication Initiative commend the Department of Health, government agencies, partners and civil society efforts that ended the polio outbreak in the country.

Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):
:: Afghanistan: one cVDPV2 case
:: Burkina Faso: two cVDPV2 cases
:: Benin: one cVDPV2 case
:: Congo: one cVDPV2 positive environmental sample
:: Côte d’Ivoire: one cVDPV2 positive environmental sample
:: DR Congo: one cVDPV2 case
:: Ethiopia: six cVDPV2 cases
:: Niger: one cVDPV2 case and one cVDPV2 positive environmental sample
:: Senegal: five cVDPV2 cases



WHO/OCHA Emergencies


Editor’s Note:
WHO has apparently reorganized and fundamentally shifted how it judges and tracks “emergencies”. We found no announcement of descriptive information to share and present the webpage structure as encountered below. Obviously, the dates associated with some of these emergencies suggest that this is an archival platform as well as a current emergencies resource.

Health emergencies list – WHO
“The health emergencies list details the disease outbreaks, disasters and humanitarian crises where WHO plays an essential role in supporting countries to respond to and recover from emergencies with public health consequences.”


Ebola outbreak, Democratic Republic of the Congo, 2021 [last apparent update
[Last apparent update: 3 May 2021]

Ebola outbreak outbreak, N’Zerekore, Guinea, 2021 [Last apparent update: 3 May 2021]

Coronavirus disease (COVID-19) pandemic [Last apparent update 18 June 2021]

Ebola outbreak, Equateur Province, Democratic Republic of the Congo, 2020 [Last apparent update: 1 June 2021]

Ebola outbreak, North Kivu, Ituri, Democratic Republic of the Congo, 2018 – 2020 [Last apparent update: 3 May 2021]

Ebola outbreak, Democratic Republic of the Congo, 2018 [Last apparent update: 24 July 2018]

Yemen crisis [Last apparent update: 12 February 2021]

Syria crisis [Last apparent update: 3 May 2021]
:: 18 June 2021 Statement
United Nations statement on the renewal of humanitarian lifeline to millions of people in north-west Syria

Somalia crisis [Last apparent update: 9 May 2018]

Nigeria crisis [Last apparent update: 3 May 2021]

Ebola outbreak, Democratic Republic of the Congo, 2017 [Last apparent update: 3 May 2021]


Zika virus disease outbreak, 2015-2016 [Last apparent update: 24 Jan 2020]

Ebola outbreak: West Africa, 2014-2016 [Last apparent update: 3 May 2021]

Iraq crisis [Last apparent update: 9 Jan 2008]

South Sudan crisis [Last apparent update: 23 Jan 2020]

Avian influenza A (H7N9) virus outbreak [Last apparent update: 24 May 2021]

Middle East respiratory syndrome (MERS-CoV) outbreak [Last apparent update: 18 July 2019]

Influenza A (H1N1) virus, 2009-2010 pandemic [Last apparent update: 10 Aug 2010]



UN OCHA – Current Emergencies
Current Corporate Emergencies
Ethiopia – Tigray Region Humanitarian Update Situation Report, 17 June 2021
:: The Integrated Food Security Phase Classification (IPC) shows that over 350,000 people are already facing catastrophic conditions (IPC 5).
:: Since the Northern Ethiopia response plan on 1 May, over 2.3 million people were reached with food aid out of the targeted 5.2 million, reaching additional 654,000 people last week
:: More than 500 cases of gender-based violence, including rape, officially reported in May. About 70 cases are against girls under 18.
:: Some 5,500 displaced people sheltering at Axum University were moved to relocation sites in Shire.
:: Partners continue to access previously hard-to-reach areas, particularly in rural remote areas, mapping dozens of locations with unexploded ordnances and remnants of war.



WHO & Regional Offices [to 19 Jun 2021]

WHO & Regional Offices [to 19 Jun 2021]
Selected News Releases/Statements
18 June 2021
United Nations statement on the renewal of humanitarian lifeline to millions of people in north-west Syria

17 June 2021
Departmental news
Public consultation of experts to join the Guideline Development Group (GDG) for the mental health gap action programme (mhGAP) guideline update

17 June 2021
News release
One in 100 deaths is by suicide

17 June 2021
Departmental news
WHO releases new global lists of high-burden countries for TB, HIV-associated TB and drug-resistant TB

16 June 2021
Departmental news
Caesarean section rates continue to rise, amid growing inequalities in access: WHO

15 June 2021
News release
Soaring e-waste affects the health of millions of children, WHO warns

15 June 2021
Departmental news
Updated recommendations for use of Pfizer–BioNTech, Moderna and Janssen vaccines against COVID-19
The interim recommendations  for use of Pfizer-BioNTech BNT162b2, Moderna mRNA–1273 and Janssen Ad26.COV2.S vaccines have been updated to reflect latest evidence.
Pfizer-BioNTech BNT162b2 vaccine
Moderna mRNA–1273 vaccine
Janssen Ad26.COV2.S vaccine



Weekly Epidemiological Record, Vol. 96, No. 24, pp. 229–240 18 June 2021
:: Progress towards rubella elimination – WHO European Region, 2005–2019



WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
:: Tackling surges in severe COVID-19 cases in Africa 11 June 2021
Africa has the highest global mortality rate among critically ill COVID-19 patients despite having the world’s lowest COVID-19 infections and deaths overall, a recent study published by the Lancet found. Shortage of critical care resources and their underuse are some of the contributing factors. Dr Christian Owoo, a Senior Lecturer in the Department of Anaesthesia, University of Ghana Medical School and a Consultant Anaesthetist/Intensivist and Head of Intensive Care Unit at Korle Bu Teaching Hospital in Accra, discusses ways to prevent severe COVID-19 illness and avert a surge in deaths.

WHO Region of the Americas PAHO
No new digest content identified

WHO South-East Asia Region SEARO
No new digest content identified

WHO European Region EURO
:: Q&A on life outside the home this summer – keeping yourself and others safe from COVID-19 18-06-2021
:: Breakthrough WHO initiative launched in Europe to engage and empower civil society organizations in health emergency responses 16-06-2021
:: Strengthening health system preparedness for mass casualty incidents: first WHO Academy learning programme in Europe 15-06-2021
:: European Region needs to scale up efforts to prevent violence against children, new report says 15-06-2021
:: New WHO/Europe information series highlights the transformation of primary health care during COVID-19 15-06-2021

WHO Eastern Mediterranean Region EMRO
:: Russian Federation donates shipment of medical kits to Afghanistan 15 June 2021
:: Third national polio immunization campaign begins in Afghanistan 14 June 2021

WHO Western Pacific Region
No new digest content identified

MMWR News Synopsis Friday, June 18, 2021

MMWR News Synopsis Friday, June 18, 2021
:: Hepatitis A Virus Infections Among Men Who Have Sex with Men — Eight U.S. States, 2017–2018
:: Mental Health Among Parents of Children Aged <18 Years and Unpaid Caregivers of Adults During the COVID-19 Pandemic — United States, December 2020 and February–March 2021
:: COVID-19 Vaccination Coverage Among Pregnant Women During Pregnancy — Eight Integrated Health Care Organizations, United States, December 14, 2020–May 8, 2021 (Early Release June 15, 2021)

Africa CDC [to 19 Jun 2021]

Africa CDC [to 19 Jun 2021]
Press Releases
The World Bank and the African Union’s COVID-19 Africa Vaccine Acquisition Task Team (AVATT) agree to work together to deploy vaccines for 400million Africans
14 June 2021 – The President of the World Bank, Mr David Malpass, and his senior management team comprised of Dr Axel van Trotsenburg and Dr Makhtar Diop met with the African Union’s COVID-19 Vaccine Acquisition Task Team (AVATT) to discuss modalities for a partnership that will accelerate vaccine deployment to Africa.

In a historic COVID-19 vaccine procurement agreement signed on 28 March 2021, the AVATT had previously successfully secured up to 400 million doses of the Johnson and Johnson single-shot COVID-19 vaccine with the support of the African Export-Import Bank (Afreximbank). “In providing a US$2billion guarantee on behalf of the African Union member states, we were able to help put Africa in a strong negotiating position with producers as we negotiated vaccine procurement. It was obvious to us at AVATT that no deal will have been possible without a strong financial backing“ the President of Afreximbank, Prof Benedict Oramah said.

“The Johnson and Johnson doses are a critical step towards the continental goal of vaccinating at least 60 per cent of Africans. Reaching this target is a prerequisite to saving African lives and livelihoods, safely reopening our economies and resuming our economic development agenda.” said Dr John N Nkengasong, Director of the African Centres for Disease Control and Prevention (Africa CDC) and Member of the AVATT.

With over 41 countries at different stages of finalising their orders for purchasing the vaccine and with vaccination momentum growing, it is essential that countries feel they can get sufficient doses quickly and in an affordable way.


The World Bank’s decision to partner with AVATT on the heels of the US announcement about dose sharing means countries can be assured they can both access and finance the vaccines they need, “ said Mr Strive Masiyiwa, African Union Special Envoy and coordinator of the AVATT.

Under the AVATT structure, AU Member States are allocated vaccines according to the size of their populations for purchase through a pooled procurement mechanism. These vaccines complement the vaccines offered through the COVAX Facility, which has set out to deliver vaccines for up to 30 per cent of participating countries’ populations, to enable the AU Member States to reach the continental target…

The World Bank team and the AVATT team agreed to fast track all administrative procedures in order to ensure vaccines get into countries as early as possible.

Once the vaccines arrive in the Member States, additional efforts will be required to support their deployment. This includes in-country distribution (logistics and storage in line with the cold-chain requirements), securing the required systems,  capacities and capabilities for vaccination. It also includes targeted research and campaigns to identify and address vaccine hesitancy through clear and targeted risk communication and community engagement. These activities will require a significant lift by countries; the additional support is going to be critical…


Full scale, interactive dashboard available at:

China CDC

China CDC
CCDC Weekly – Weekly Reports: Current Volume (3)
2021-06-18 / No. 25
PDF of this issue
:: Policy Notes: Interpretation of the Protocol for Prevention and Control of COVID-19 in China (Edition 8)
:: Preplanned Studies: Willingness of the General Public to Receive the COVID-19 Vaccine During a Second-Level Alert — Beijing Municipality, China, May 2020
:: Perspectives: Caution About Truncation-By-Death in Clinical Trial Statistical Analysis: A Lesson from Remdesivir
:: Notes from the Field: Genome Characterization of COVID-19 Lineage B.1.1.7 Detected in the First Six Patients of a Cluster Outbreak — Shenzhen City, Guangdong Province, China, May 2021
:: Notes from the Field: Three Cases of COVID-19 Variant Delta With and Without Vaccination — Chengdu City, Sichuan Province, April–May, 2021
:: Notifiable Infectious Diseases Reports: Reported Cases and Deaths of National Notifiable Infectious Diseases — China, April, 2021

National Health Commission of the People’s Republic of China [to 19 Jun 2021]
June 19: Daily briefing on novel coronavirus cases in China
On June 18, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 30 new cases of confirmed infections

China delivers additional batch of Sinovac vaccines to Philippines

China approves emergency use of domestic vaccines for 3-17 age group
Updated: 2021-06-15 | Xinhua
[See COVID – China above for detail]

National Medical Products Administration – PRC [to 19 Jun 2021]
Over 945m doses of COVID-19 vaccines administered in China
More than 945.1 million doses of COVID-19 vaccines have been administered in China as of Wednesday, the National Health Commission said on June 17.

China’s NMPA, Indonesian BPOM sign MoU on Regulatory Cooperation of Pharmaceutical Products and Cosmetics
In order to jointly respond to global public health challenges, China’s NMPA and Indonesian BPOM have agreed to strengthen regulatory cooperation.